30 closest matches · ranked by relevance
Blood Brain Barrier Defect
Primary: Change in AUC0-18 of the Temozolomide Concentration (AUC-T) in Brain Interstitium Before and After Regadenoson Infusion — 19.1; 18.0 percentage of AUC
Pediatric Traumatic Brain Injury
Primary: Number of Participants Who Experienced Adverse Events — 0; 2 participants
Alzheimer Disease
Primary: Total Number of Individuals With Successful Opening of the BBB — 5 Participants
Glioblastoma
Primary: Progression-Free Survival — 7.71 weeks
Brain Metastases
Primary: Percentage of the Gross Tumor Volume With a BTB Opening of Ktrans > 0.005 Min-1 — 78.6; 85.6; 6.4; 74.4 percentage of gross tumor volume
Astrocytoma, Grades II, III and IV · Glioblastoma Multiforme · Giant Cell Glioblastoma
Primary: Number of Participants With the Presence of Drug in the Tumor Tissue — 2 Participants
Traumatic Brain Injury
Primary: Number of Participants With Improved Cerebral Perfusion — 8 Participants
Subarachnoid Hemorrhage, Aneurysmal · Vasospasm, Cerebral
Primary: Number of Participants Who Develop Delayed Cerebral Vasospasm — 2 Participants
Glioblastoma Multiforme · Brain Tumor
Primary: Progression-free Survival (PFS) — 91.3 percentage of participants
Severe Traumatic Brain Injury
Primary: Fraction of Time That Brain Oxygen Levels Are Below the Critical Threshold of 20 mm Hg . — 0.15; 0.44 Proportion
Alzheimer Disease
Primary: Microglial Activation Reserve Index (MARI) — 17.7; 30.1 percentage of MARI — p=0.14
Organic Brain Syndrome, Nonpsychotic · Neurocognitive Disorders · Mental Disorder, Organic
Primary: The Number of Patients With Severe Adverse Events and Adverse Reactions — 0 Participants
Pharmacokinetics
Primary: Unbound Ceftolozane Exposure in the Plasma — 322.6 mg*h/L
Glioblastoma
Primary: To Measure the Reproducibility of qDCE-MRI Measurement of Glioblastoma. — 5 %COV
Alzheimer Disease
Primary: Cerebral Blood Flow Global — -2.2 ml/100g/min — p=.002
Obstructive Sleep Apnea Syndrome
Primary: Change in Cerebral Blood Flow (CBF) at Baseline Between Obstructive Sleep Apnea Syndrome (OSAS) and Controls — 184; 209 percentage of change from baseline
Malignant Glioma
Primary: Maximum Tolerated Dose (MTD) of MK-3475 When Combined With MLA - Phase I Only — 200 mg
Peroxisome Biogenesis Disorders
Primary: Peroxisome Biochemical Functions as Measured by Plasma Very Long Chain Fatty Acid — 0.180; 0.188 ratio
Craniosynostosis
Primary: Blood Flow and Perfusion — 26.8 ml/min/100g — p=0.004
Hemostasis · Meningioma Surgery
Primary: Hemostasis at the Target Bleeding Site (TBS) at 6 Minutes Following Treatment Application. Hemostasis is Defined as no Detectable Bleeding at the TBS. — 99.2; 100 % of…
Recurrent Glioblastoma
Primary: Number of Patients With a Decrease in Median Tumor SUV — 6 Participants
Glucose Transporter Type 1 Deficiency Syndrome · GLUT1 Deficiency Syndrome
Primary: Number of Participants With Reduction in Spike-wave Fraction of the EEG Recording Time — 13 Participants
Cerebral Amyloid Angiopathy
Primary: Change From Baseline to Day 2 in Cerebrovascular Reactivity as Measured by the Slope (Amplitude Over Time to Peak) From Visual Task-evoked Functional Magnetic Resonance…
Hyperbilirubinemic Encephalopathy
Primary: Bilirubin Induced Neurologic Dysfunction II Score (BIND II) — 1 units on a scale
Glioblastoma
Primary: Increase of Interferon Gamma Levels — 0 Participants
Traumatic Brain Injury (TBI) · Healthy
Primary: Receptor Binding (Vt) — 2.53; 2.21; 3.21; 3.22 mL/cm^3
Chronic Traumatic Brain Injury
Primary: Change From Baseline of Concentrations of Essential Amino Acid at 1.5 Hours After Eating — 487.28; 553.70; 1224.19; 1339.54 µM
Glioblastoma · Glioblastoma With Primitive Neuronal Component · Gliosarcoma
Primary: Proportion of Progression Free Survival Participants (PFS) at Six Months — 0.786 Proportion of participants
Radiation Necrosis
Primary: Change in Radiation Necrosis and Cerebral Edema After a Single Treatment of Low Dose Intra-arterial Avastin (Bevacizumab) — 86.8; 38.6; 32.6; 14.5 cm^3 — p=0.012
Metastatic Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Objective Radiographic Tumor Response in Patients With Recurrent Solid Tumor Brain Metastases Treated With Bevacizumab — 2 Participants